Will EFU Health and Jubilee General cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Fabhalta is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DRAP?

The DRAP named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DRAP review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Pakistani-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Pakistan Medical and Dental Council (PMDC) and DRAP verifies the active license; the DRAP application records both the prescribing physician and the dispensing facility.

Can I receive Fabhalta at home?

The dispensing facility must be Pakistani-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 18,000 to 19,500 per month. Delivered quote within 24h.Get my quote

Fabhalta access in Pakistan: the DRAP named-patient pathway

How patients in the Islamic Republic of Pakistan legally obtain Fabhalta (iptacopan) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Pakistan access Fabhalta (iptacopan) for paroxysmal nocturnal hemoglobinuria (PNH) in adults, IgA nephropathy in adults at risk of rapid disease progression, and complement-3-glomerulopathy (C3G) through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in PKR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Fabhalta reaches patients in Pakistan

Fabhalta (iptacopan, a first-in-class oral selective Factor B inhibitor of the alternative complement pathway, FDA-approved December 2023 for paroxysmal nocturnal haemoglobinuria, August 2024 for IgA nephropathy in adults at risk of rapid disease progression, and March 2025 for complement-3 glomerulopathy) is not visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification as of 2026-05-31. Access in Pakistan runs through the Special Permission for Import of Therapeutic Goods for Personal Use, filed at dra.gov.pk/therapeutic-goods/import-export/special-permissions. The Fabhalta-specific clinical justification depends on indication: for PNH, GPI-anchor-deficient clone confirmation by flow cytometry plus haemolysis markers; for IgAN, biopsy-confirmed IgA nephropathy with proteinuria of 1.5 g per day or greater on optimised RAS blockade; for C3G, biopsy-confirmed C3 glomerulopathy. Critical safety requirement: vaccination against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B at least 2 weeks before initiation per the FDA Boxed Warning; DRAP reviewers expect the prescribing nephrologist or haematologist to document the vaccination schedule in the application. Treatment is oral 200 mg twice daily, chronic. DRAP processing is several working days when documentation is complete. The NOC is single-consignment and is re-filed per cycle for chronic therapy.

Where Fabhalta is dispensed in Pakistan

Fabhalta is an oral therapy split across two specialty axes (PNH on haematology; IgAN and C3G on nephrology) and the dispensing setting depends on the indication. For PNH cases the relevant Pakistani tertiary haematology nodes are the Aga Khan University Hospital Department of Haematology in Karachi at hospitals.aku.edu, the National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD) in Karachi (the national haemoglobinopathy and complement-disease registry), and the SKMCH and RC Haematology and Medical Oncology Service in Lahore at shaukatkhanum.org.pk. For IgAN and C3G cases the relevant Pakistani tertiary nephrology nodes are the Sindh Institute of Urology and Transplantation (SIUT) in Karachi, a global reference centre for renal disease and transplantation with a structured glomerular-disease service; the Aga Khan University Hospital Section of Nephrology in Karachi; the Shifa International Hospital Department of Nephrology in Islamabad; and the Punjab Institute of Nephrology and Urology in Lahore. SIUT is the most-likely point of contact for biopsy-proven IgAN or C3G cases nationally because of its registry depth and renal pathology capability. The vaccination-before-initiation requirement is operationally co-managed with infectious diseases or vaccination clinics at the same tertiary centre.

What Fabhalta costs in Pakistan

The US reference WAC for Fabhalta is approximately USD 19,000 to USD 21,000 per 30-day supply at the labelled dose of 200 mg twice daily per Novartis disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at the labelled dose runs in the range of USD 225,000 to USD 250,000. No public local-currency benchmark for Fabhalta in PKR is observed on the DRAP MRP database or in Pakistani patient-organisation reporting as of 2026-05-31; do not estimate. Price snapshot: 2026-05-31. Cost layers: ambient-temperature international logistics into Pakistan (low to mid four-figure USD; Fabhalta is a stable oral capsule and does not require cold-chain), DRAP permit and customs duties (nominal), the dispensing hospital's nephrology or haematology consultation and surveillance fees (urine PCR, eGFR, LDH, complement assay schedule), pre-treatment vaccination cost (which is non-trivial when administered as a complete meningococcal-pneumococcal-Hib panel), and the Reserve Meds concierge fee itemised separately. State Bank of Pakistan outward remittance allowance for medical purposes governs wire scheduling.

Funding and access barriers for Fabhalta in Pakistan

PNH is rare (incidence approximately 1.3 per million per year); IgAN is the most common primary glomerulonephritis globally and the Pakistani biopsy series rates among the highest IgAN prevalence in South Asia (publications from SIUT and AKUH place IgAN as the leading primary glomerulonephritis in adult Pakistani biopsies). This drives a clinically meaningful Fabhalta-eligible IgAN population but very limited public-funding precedent. The Sehat Sahulat Programme and provincial Sehat Card Plus do not list iptacopan; case-by-case adjudication is the only documented route. Pakistan Bait-ul-Mal grants are means-tested. Major private insurers (Jubilee Life, EFU Life, State Life, Adamjee Life) do not list iptacopan on retail formularies; corporate group policies require step-therapy documentation (for IgAN, demonstrated failure of optimised RAS blockade with persistent proteinuria of 1 g per day or greater; for PNH, eculizumab or ravulizumab failure or intolerance, recognising neither is universally available in Pakistan). The Boxed Warning requirement for pre-treatment meningococcal and pneumococcal vaccination is an operational gating step that drives the DRAP submission timeline (the vaccination certificate is a required document in the package). The import-permit experience for an oral capsule is straightforward; the access constraint is funding rather than logistics.

Recent regulatory and access news for Fabhalta

FDA expanded the Fabhalta label (March 2025) to add C3 glomerulopathy in adults, the first FDA-approved therapy for C3G; the approval is summarised at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) issued a positive opinion for Fabhalta in IgA nephropathy in 2024; European approval followed. Novartis launched a global expanded-access programme for Fabhalta in C3G in selected regions in 2025. No DRAP-specific bulletin on Fabhalta or the complement-inhibitor class has been observed over the last 12 months as of 2026-05-31. The DRAP consolidated Guidance Document for Imports and Exports of Therapeutic Goods at dra.gov.pk regulatory updates remains the procedural reference for Pakistani named-patient applications.

Where Reserve Meds fits in Fabhalta cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Fabhalta specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Fabhalta case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Fabhalta's oral once-twice-daily dosing changes the PNH treatment paradigm relative to infused C5 inhibitors; named-patient files document the meningococcal vaccination status mandated by the FDA label. Pakistani specialty referral concentrates these cases at AKU Karachi and Shaukat Khanum (oncology).

Next step

If your Pakistani physician has prescribed Fabhalta and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Fabhalta case Or message us on WhatsApp